Quick Facts

• Primary Use: Adjunctive management of diarrhea.
• Therapeutic Domain: Helps to decrease the number and frequency of bowel movements.
• Patient Group: Indicated for use in patients 13 years of age and older.

---

Reasec (diphenoxylate and atropine sulfate) is used as an additional measure in the overall management of diarrhea. It is typically prescribed alongside fluid and electrolyte replacement therapy to help control symptoms. The medication works by promoting a reduction in the activity of an overactive bowel, which may help decrease the frequency of unformed stool.

This agent is utilized when therapeutic needs suggest the use of an antimotility medication to support the patient’s recovery from diarrhea. Clinical improvement in symptoms is generally observed within 48 hours of starting a regimen. If a therapeutic effect is not achieved after ten days of treatment, the medication should be discontinued.

Reasec is indicated as adjunctive therapy in the management of diarrhea in patients who are 13 years of age and older.

Regulatory References

1. DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE solution - DailyMed - NIH

The eligibility profile for Reasec is strictly defined by regulatory authorities and centers on age, underlying conditions, and physiological status. The medicine is officially indicated for patients 13 years of age and older. Use is absolutely contraindicated in pediatric patients less than six years old due to the documented risks of severe respiratory and central nervous system depression.

Contraindications and Restrictions

Absolute prohibitions include patients with obstructive jaundice or those with diarrhea caused by enterotoxin-producing bacteria (such as Clostridium difficile). It is also contraindicated for patients with a known hypersensitivity to either diphenoxylate or atropine.

Use requires extreme caution or is restricted in the following contexts:

• Organ Function: Patients with advanced hepatorenal disease or abnormal liver function must be monitored closely.
• Fluid Status: The medicine should be withheld if severe dehydration or electrolyte imbalance is present until corrective therapy is initiated.
• Pregnancy and Lactation: Use is permitted only if the anticipated benefit justifies the potential risk to the fetus or infant, as determined by official labeling.

Contraindicated Combinations

Co-administration with Monoamine Oxidase Inhibitors (MAOIs) is formally prohibited. This restriction is documented in the official prescribing information due to the theoretical potential for a systemic hypertensive crisis.

Interactions with CNS Depressants and Alcohol

The regulatory profile details a significant pharmacodynamic interaction risk when the drug is used concurrently with substances that act on the central nervous system. Co-administration with alcohol or other CNS depressants, which include tranquilizers, opioids, barbiturates, and specific muscle relaxants, may result in the potentiation of depressant effects. This constitutes an additive pharmacodynamic interaction, where the effect of diphenoxylate may be enhanced. No specific pharmacokinetic interactions involving CYP enzymes or drug transporters are formally detailed in the official label, nor are mandatory timing separation rules required for co-administration.

Population-Specific Interaction Caution

An important consideration documented in the regulatory information is the interaction relevance in specific patient populations. The medication must be used with extreme caution in individuals with advanced hepatorenal disease or abnormal liver function. In this context, the interaction risk is heightened due to the potential for precipitating hepatic coma.

Peripheral mu-Opioid Agonism and Motor Suppression

Diphenoxylate's primary mechanism involves acting as a direct agonist on peripheral mu-opioid receptors (MOR), which are located on enteric neurons within the intestinal wall. This binding action reduces the excitability threshold of the Enteric Nervous System (ENS), resulting in a decrease in propulsive motor activity (peristalsis).

---

Neurotransmitter Inhibition and Fluid Regulation

Activation of the MOR initiates an intracellular cascade that inhibits the presynaptic release of Acetylcholine (ACh), the key excitatory neurotransmitter for muscular contraction. This reduction in propulsive movement prolongs Intestinal Transit Time, which is the physiological change that alters fluid dynamics by facilitating greater passive reabsorption of water and electrolytes in the colon.

---

Mechanistic Role of Sub-Therapeutic Atropine

The second component, Atropine, acts as a muscarinic receptor antagonist, included to engage its mechanism at supratherapeutic concentrations. The compound is present at a concentration that causes negligible impact on the primary mechanism. Its mechanism of muscarinic antagonism, generating predictable anticholinergic effects, acts as a pharmacological deterrent at high concentrations.

How Reasec (Diphenoxylate and Atropine) is Used: Administration Guidelines

Reasec, a combination product containing diphenoxylate hydrochloride and atropine sulfate, is administered via the oral route only, available as a tablet and an oral solution. Its use is guided by age, dose, and duration, and is intended to be adjunctive to essential fluid and electrolyte therapy.

---

Standard Dosing and Frequency

For adults and pediatric patients 13 years of age and older, the initial regimen is typically 5 mg of diphenoxylate (equivalent to two tablets or 10 mL of liquid) taken four times daily (q.i.d.). The maximum daily dose is 20 mg of diphenoxylate.

As soon as initial control of symptoms is achieved, the dosage must be reduced to a minimum effective level, which may be as low as 5 mg once daily.

---

Use Duration and Administration Context

Treatment duration is time-limited. If no clinical improvement is observed after ten days of administering the maximum recommended daily dose, the medication should be discontinued.

The drug is intended to be administered alongside appropriate fluid and electrolyte replacement and must be withheld if severe dehydration or electrolyte imbalance is present until correction. The medication may be taken with or without food.

---

Population-Specific Rules

Age Restrictions: The tablet formulation is not approved for children younger than 13 years old. For children aged 2 to <13 years, only the oral liquid formulation is approved, and dosing is strictly weight-based (0.3 to 0.4 mg/kg/day of diphenoxylate) given in four divided doses. When using the liquid, a calibrated measuring device must be employed for accuracy. If a dose is missed, patients should not double the next dose.

Research Evidence / Overview of Studies for Reasec (Atropine SulfateDiphenoxylate)

Evidence for the Symptomatic Management of Acute and Chronic Diarrhea

The research base for this drug is rooted in historical Randomized Controlled Trials (RCTs) and older comparative studies. These studies was studied for patients experiencing conditions characterized by fluctuating or episodic manifestations of acute or persistent diarrhea. Research examined clinical endpoints such as measures of stool frequency, changes in stool consistency, and how movement was observed to affect the gastrointestinal system over time.

The findings describe patterns observed in the studies over short-term periods, typically with observation lasting less than 10 days. These short-term results, collected primarily in adults and children 13 years of age and older, contributed to the drug’s original regulatory review of its clinical evaluation. Research has also included comparative studies where the drug's effects was evaluated in relation to other common antidiarrheal agents. Long-term effects are not fully established because the follow-up durations were limited in the initial, core studies.

Evidence for Use in Specialized Diarrhea Contexts

Studies in Critically Ill Adults

Research has explored the evaluation of this medication in specific patient groups, including critically ill adult patients in the intensive care setting who are experiencing acute, non-infectious diarrhea. The research base for this application is built on Systematic Reviews that evaluated a very small number of existing Randomized Controlled Trials (RCTs). The overall evidence available for this context is recognized as limited, with some expert groups assessing the certainty of the findings as very low.

Studies in Chemotherapy- or Radiotherapy-Related Diarrhea

The combination drug was evaluated in the context of patients with diarrhea induced by chemotherapy or radiotherapy (CRT). This evidence is derived from settings with varying symptom burdens, consisting mainly of observational cohort studies and limited comparative trials. These studies examined changes in outcomes related to systemic or functional imbalance in adult cancer patients with moderate-to-severe CRT-related diarrhea. The evidence is limited because it relies more on observational data rather than large-scale, prospective RCTs.

What is Still Uncertain About the Evidence

Data for certain groups remain insufficient, including for children younger than 13 years, where formal studies to establish safety and effectiveness are not available. Limited information is available for older adults, and few studies have explored the specific effects in this population. Comparative evidence is lacking in some indications to clearly define the drug’s profile against other widely used antidiarrheal agents. Overall, findings describe group patterns, not personal outcomes.

Key Studies & References

1. Evaluation of efficacy and safety of diphenoxylate hydrochloride and atropine sulphate in patient with acute radiation or chemotherapy induced diarrhea

Common questions about Reasec (atropine sulfateDiphenoxylate) (FAQ)

Q: What should I do if I miss a dose of Reasec?

Official instructions indicate that a missed dose should typically be taken as soon as it is remembered. However, if the time is close to the next scheduled dose, the instruction is to skip the missed dose entirely. Regulatory guidelines advise patients never to double their next dose to make up for a missed one.

Q: What is the maximum dose of Reasec an adult can take in one day?

Official information defines the maximum daily amount for adults based on the active ingredient, diphenoxylate, which should not exceed 20 mg. This limit is specified as a maximum number of tablets or volume of the liquid solution.

Q: Is it safe to use Reasec (Diphenoxylate and Atropine) for diarrhea caused by an infection, like food poisoning?

The official product information contains a specific restriction against using this medicine for diarrhea caused by enterotoxin-producing bacteria. These bacteria can be the source of some infectious diarrheas, including some cases of food poisoning. It is advised to use the medication with caution in other cases of infectious diarrhea. A healthcare provider is best suited to determine if your specific condition is appropriate for treatment.

Q: Can I take Reasec (Diphenoxylate and Atropine) if I am pregnant or breastfeeding?

Official labeling addresses the use of this medication during pregnancy and breastfeeding. During pregnancy, it is only recommended if a healthcare provider determines that the potential benefit justifies any potential risk to the fetus. Regarding breastfeeding, both active ingredients are known to pass into human milk, so caution is advised, and the decision should be made with a healthcare provider.

Q: How does the atropine in Reasec help with diarrhea?

The primary anti-diarrheal effect comes from the diphenoxylate component. The atropine component is included in a minimal, subtherapeutic amount. According to the regulatory pharmacology section, the atropine is primarily intended as a deterrent to discourage the ingestion of excessively high doses of the medication, rather than providing a therapeutic benefit for diarrhea itself.

Q: Does Reasec (Diphenoxylate and Atropine) require a prescription?

Yes, this medication is regulated and requires a prescription. Official documents classify Diphenoxylate and Atropine as a Schedule V controlled substance, which means it is only available by prescription.

Diphenoxylate and Atropine must be stored according to strict regulatory guidelines to maintain potency and ensure safety as a controlled substance.

Storage Requirements

Condition	Tablets (General)	Oral Solution (Liquid)
Temperature	Controlled Room Temperature, 15 C to 30 C (59 F to 86 F)	20 C to 25 C (68 F to 77 F)
Environmental	Protect from light and moisture; keep away from excess heat; do not freeze	Protect from light and moisture; do not freeze
Container	Keep container tightly closed in a child-resistant container	Dispense and store only in the original container
Stability	Not specified (see liquid)	Discard 90 days after opening the bottle

Disposal and Child-Safety

This medication must be kept out of the reach of children and pets, and stored in a safe, secure place. Patients are required to dispose of unused or expired product by following official controlled substance guidelines. The preferred method is returning it to a drug take-back program. If unavailable, it should be mixed with undesirable material, sealed in a container, and placed in household trash to prevent misuse.